Default company panoramic image

CHX Technologies

CHX is a pharmaceutical company introducing the only proprietary, proven and approved treatment to prevent adult dental decay.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded January 2000
  • Employees 2
  • Website

Company Summary

CHX has developed and gained approval for Prevora, a clear, topical antibacterial tooth coating which is a new standard of preventive care for the older dental patient. Prevora has successfully completed all Phase III studies and is approved for a unique indication in Canada and Europe. A new drug application to the FDA is scheduled for 2014. CHX is currently testing a co-op marketing model in Southern Ontario called Partners in Prevention.


  • Default avatar
    Ross Perry

    Ross has a 20 year track record of reaching key milestones in pharmaceutical development. He is responsible for all drug approvals and for all the grants and funding raised by CHX ($25 million in total). Ross also has developed the co-op marketing model for Prevora.

  • Default avatar
    Brenda Turgeon
    Vice President

    Brenda Turgeon also has 20 years experience in reaching pharmaceutical milestones and pharmaceutical operations. She oversaw the monitoring and drug supply to all Phase III studies of Prevora, supported regulatory reviews and site audits, is responsible for drug supply and stability studies, and customer service.


  • Default avatar
    Robert Rueter (Rueter Scargall Bennett, Toronto)
    Default avatar
    Sal Formusa (Formusa Zucarro, Concord)

Previous Investors

  • Default avatar
    AGF Funds
    Default avatar
    Stone Asset Management
    Default avatar
    HNW Management